P&G in talks for Pfizer consumer health business

Apr 03, 2018

While numerous potential buyers, including GlaxoSmithKline and Johnson & Johnson, have already backed out, Procter & Gamble is still in talks with Pfizer on the sale of its consumer business according to a CNBC report. The two organizations are allegedly not close on a price.  

CNBC reporter David Faber says that while Pfizer is hoping to sell for around $20 billion, P&G's hoping to snag the consumer unite for $15 or $16 billion.

Hoping to finalize a decision by the end of the month, Pfizer is still mulling its options, which include a joint venture with other drug makers.

Read the CNBC report